Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease
Introduction: Inflammatory bowel disease (IBD) is a chronic and incurable entity. Therapy with anti-TNF-α agents was the first biologic therapy approved in Mexico for IBD. New biologic agents, such as vedolizumab and ustekinumab, have recently been added, as have small-molecule inhibitors. Aim: To u...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Revista de Gastroenterología de México (English Edition) |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2255534X21000116 |
| _version_ | 1818857304091525120 |
|---|---|
| author | J.K. Yamamoto-Furusho F.J. Bosques-Padilla M.A. Martínez-Vázquez |
| author_facet | J.K. Yamamoto-Furusho F.J. Bosques-Padilla M.A. Martínez-Vázquez |
| author_sort | J.K. Yamamoto-Furusho |
| collection | DOAJ |
| description | Introduction: Inflammatory bowel disease (IBD) is a chronic and incurable entity. Therapy with anti-TNF-α agents was the first biologic therapy approved in Mexico for IBD. New biologic agents, such as vedolizumab and ustekinumab, have recently been added, as have small-molecule inhibitors. Aim: To update the biologic therapeutic approach to IBD in Mexico with new anti-TNF-α agents and novel biologics whose mechanisms of action induce and maintain remission of Crohn’s disease and ulcerative colitis (UC). Materials and methods: Mexican specialists in the areas of gastroenterology and inflammatory bowel disease were summoned to participate. The consensus was divided into 3 modules, with 49 statements. The Delphi method was applied, sending the statements to all participants to be analyzed and edited, before the face-to-face meeting. During said meeting, the clinical studies were shown, emphasizing the level of clinical evidence, and the final discussion and voting round on the level of agreement of all the statements was conducted. Results: In this second Mexican consensus, recommendations are made for new anti-TNF-α agents, such as golimumab, new biologics with other mechanisms of action, such as vedolizumab and ustekinumab, as well as for the small-molecule inhibitor, tofacitinib. Conclusions: The updated recommendations focus on patient-reported outcomes, biologic therapy, small-molecule inhibitors, and the safety aspects of each of the drugs. Resumen: Antecedentes: La enfermedad inflamatoria intestinal (EII) es una entidad crónica e incurable. La terapia con agentes anti-TNF alfa fue la primera terapia biológica aprobada en México en EII. Recientemente han aparecido nuevos agentes biológicos como el vedolizumab y ustekinumab así como inhibidores de moléculas pequeñas. Objetivo: Actualizar el enfoque terapéutico biológico de la EII en nuestro país con nuevos agentes anti-TNF alfa y nuevos mecanismos de acción para la inducción y mantenimiento de remisión de la enfermedad de Crohn y colitis ulcerosa crónica idiopática (CUCI). Material y Métodos: Se invitaron a especialistas de la República Mexicana de las áreas de Gastroenterología y Enfermedad Inflamatoria Intestinal. Se dividió el consenso en 3 módulos, con 49 enunciados. Se aplicó el método de panel Delphi, para ello se envió las preguntas previó a la reunión a todos los participantes para que fueran editadas y ponderadas. Durante la reunión presencial se mostraron los estudios clínicos dando énfasis al nivel de evidencia clínica y se llevó a cabo la discusión y votación final del grado de acuerdo en todos los enunciados. Resultados: Es el segundo consenso mexicano en donde se establecen las recomendaciones para nuevos anti-TNF alfa como el golimumab y otros mecanismos de acción como vedolizumab, ustekinumab y tofacitinib. Conclusiones: Las recomendaciones actualizadas se centran en los resultados informados por los pacientes, la terapia biológica, los inhibidores de moléculas pequeñas y los aspectos de seguridad de cada uno. |
| first_indexed | 2024-12-19T08:38:16Z |
| format | Article |
| id | doaj.art-d513430d644a4198b6e3f182f34a2bc0 |
| institution | Directory Open Access Journal |
| issn | 2255-534X |
| language | English |
| last_indexed | 2024-12-19T08:38:16Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Revista de Gastroenterología de México (English Edition) |
| spelling | doaj.art-d513430d644a4198b6e3f182f34a2bc02022-12-21T20:29:00ZengElsevierRevista de Gastroenterología de México (English Edition)2255-534X2021-01-018617085Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel diseaseJ.K. Yamamoto-Furusho0F.J. Bosques-Padilla1M.A. Martínez-Vázquez2Clínica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Corresponding author at: Clínica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Colonia Belisario Domínguez Sección XVI, Alcaldía Tlalpan, C.P. 14080, Mexico City, Tel: +55 55 73 34 18, Fax: +55 56 55 09 42.Departamento de Gastroenterología, Hospital Universitario de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, MexicoHospital Zambrano Hellion TecSalud, Monterrey, Nuevo León, MexicoIntroduction: Inflammatory bowel disease (IBD) is a chronic and incurable entity. Therapy with anti-TNF-α agents was the first biologic therapy approved in Mexico for IBD. New biologic agents, such as vedolizumab and ustekinumab, have recently been added, as have small-molecule inhibitors. Aim: To update the biologic therapeutic approach to IBD in Mexico with new anti-TNF-α agents and novel biologics whose mechanisms of action induce and maintain remission of Crohn’s disease and ulcerative colitis (UC). Materials and methods: Mexican specialists in the areas of gastroenterology and inflammatory bowel disease were summoned to participate. The consensus was divided into 3 modules, with 49 statements. The Delphi method was applied, sending the statements to all participants to be analyzed and edited, before the face-to-face meeting. During said meeting, the clinical studies were shown, emphasizing the level of clinical evidence, and the final discussion and voting round on the level of agreement of all the statements was conducted. Results: In this second Mexican consensus, recommendations are made for new anti-TNF-α agents, such as golimumab, new biologics with other mechanisms of action, such as vedolizumab and ustekinumab, as well as for the small-molecule inhibitor, tofacitinib. Conclusions: The updated recommendations focus on patient-reported outcomes, biologic therapy, small-molecule inhibitors, and the safety aspects of each of the drugs. Resumen: Antecedentes: La enfermedad inflamatoria intestinal (EII) es una entidad crónica e incurable. La terapia con agentes anti-TNF alfa fue la primera terapia biológica aprobada en México en EII. Recientemente han aparecido nuevos agentes biológicos como el vedolizumab y ustekinumab así como inhibidores de moléculas pequeñas. Objetivo: Actualizar el enfoque terapéutico biológico de la EII en nuestro país con nuevos agentes anti-TNF alfa y nuevos mecanismos de acción para la inducción y mantenimiento de remisión de la enfermedad de Crohn y colitis ulcerosa crónica idiopática (CUCI). Material y Métodos: Se invitaron a especialistas de la República Mexicana de las áreas de Gastroenterología y Enfermedad Inflamatoria Intestinal. Se dividió el consenso en 3 módulos, con 49 enunciados. Se aplicó el método de panel Delphi, para ello se envió las preguntas previó a la reunión a todos los participantes para que fueran editadas y ponderadas. Durante la reunión presencial se mostraron los estudios clínicos dando énfasis al nivel de evidencia clínica y se llevó a cabo la discusión y votación final del grado de acuerdo en todos los enunciados. Resultados: Es el segundo consenso mexicano en donde se establecen las recomendaciones para nuevos anti-TNF alfa como el golimumab y otros mecanismos de acción como vedolizumab, ustekinumab y tofacitinib. Conclusiones: Las recomendaciones actualizadas se centran en los resultados informados por los pacientes, la terapia biológica, los inhibidores de moléculas pequeñas y los aspectos de seguridad de cada uno.http://www.sciencedirect.com/science/article/pii/S2255534X21000116Enfermedad de CrohnCUCIAnti-TNF alfaVedolizumabUstekinumabTofacitinib |
| spellingShingle | J.K. Yamamoto-Furusho F.J. Bosques-Padilla M.A. Martínez-Vázquez Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease Revista de Gastroenterología de México (English Edition) Enfermedad de Crohn CUCI Anti-TNF alfa Vedolizumab Ustekinumab Tofacitinib |
| title | Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease |
| title_full | Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease |
| title_fullStr | Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease |
| title_full_unstemmed | Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease |
| title_short | Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease |
| title_sort | second mexican consensus on biologic therapy and small molecule inhibitors in inflammatory bowel disease |
| topic | Enfermedad de Crohn CUCI Anti-TNF alfa Vedolizumab Ustekinumab Tofacitinib |
| url | http://www.sciencedirect.com/science/article/pii/S2255534X21000116 |
| work_keys_str_mv | AT jkyamamotofurusho secondmexicanconsensusonbiologictherapyandsmallmoleculeinhibitorsininflammatoryboweldisease AT fjbosquespadilla secondmexicanconsensusonbiologictherapyandsmallmoleculeinhibitorsininflammatoryboweldisease AT mamartinezvazquez secondmexicanconsensusonbiologictherapyandsmallmoleculeinhibitorsininflammatoryboweldisease |